Characterisation of the retinal phenotype using multimodal imaging in novel compound heterozygote variants of CYP2U1

Purpose To report the retinal phenotype in two patients simulating type 2 macular telangiectasis with new variants in CYP2U1 implicated in Hereditary Spastic Paraplegia type 56 (HSP 56). Methods Five members of a non-consanguineous family (parents and three male children) were investigated. All family members underwent a full ophthalmological evaluation and multimodal retinal imaging. Two family members demonstrating retinal anomalies underwent additional OCT angiography, dual wavelength autofluorescence and fluorescence lifetime imaging ophthalmoscopy, kinetic perimetry, fundus-correlated microperimetry, electroretinography and electro-oculography. Whole exome sequencing was performed in all five family members. Results The two siblings with compound heterozygous novel variants c.452C>T; p.(Pro151Leu), c.943C>T; p.(Gln315Ter) in CYP2U1 demonstrated parafoveal loss of retinal transparency and hyperreflectivity to blue light, redistribution of luteal pigment to the parafoveal edge, photoreceptor loss, FLIO anomalies: a pattern compatible with that seen in macular telangiectasia type 2 (MacTel). One had manifest neurological abnormalities since early childhood, the second had no neurological abnormalities. Each parent and the third sibling were heterozygous for one variant and were neurologically and ophthalmologically normal. Conclusion These CYP2U1 variants are associated with a retinal phenotype very similar to that otherwise specific for MacTel, suggestive of possible links in the aetiology/pathogenesis of these diseases.

[1]  J. Zenteno,et al.  Clinical-genetic findings in a group of subjects with macular dystrophies due to mutations in rare inherited retinopathy genes , 2022, Graefe's Archive for Clinical and Experimental Ophthalmology.

[2]  A. Durr,et al.  Implication of folate deficiency in CYP2U1 loss of function , 2021, The Journal of experimental medicine.

[3]  P. Charbel Issa,et al.  Mitochondrial Retinopathy. , 2021, Ophthalmology. Retina.

[4]  Marin L. Gantner,et al.  Serine biosynthesis defect due to haploinsufficiency of PHGDH causes retinal disease , 2021, Nature Metabolism.

[5]  A. Durr,et al.  Pseudoxanthoma elasticum overlaps hereditary spastic paraplegia type 56 , 2020, Journal of internal medicine.

[6]  J. Dowling,et al.  A connectomics approach to understanding a retinal disease , 2020, Proceedings of the National Academy of Sciences.

[7]  T. Peto,et al.  Genetic disruption of serine biosynthesis is a key driver of macular telangiectasia type 2 aetiology and progression , 2020, bioRxiv.

[8]  J. Pedroso,et al.  Ophthalmological changes in hereditary spastic paraplegia and other genetic diseases with spastic paraplegia , 2019, Journal of the Neurological Sciences.

[9]  Marin L. Gantner,et al.  Serine and Lipid Metabolism in Macular Disease and Peripheral Neuropathy. , 2019, The New England journal of medicine.

[10]  E. Chew,et al.  Progression characteristics of ellipsoid zone loss in macular telangiectasia type 2 , 2019, Acta ophthalmologica.

[11]  I. Constable,et al.  Effect of Ciliary Neurotrophic Factor on Retinal Neurodegeneration in Patients with Macular Telangiectasia Type 2: A Randomized Clinical Trial. , 2019, Ophthalmology.

[12]  György Hajnóczky,et al.  Coming together to define membrane contact sites , 2019, Nature Communications.

[13]  P. Bernstein,et al.  Genetic Penetrance of Macular Telangiectasia Type 2 , 2018, JAMA ophthalmology.

[14]  Martin Hammer,et al.  Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO) of Macular Pigment , 2018, Investigative ophthalmology & visual science.

[15]  A. Durr,et al.  CYP2U1 activity is altered by missense mutations in hereditary spastic paraplegia 56 , 2018, Human mutation.

[16]  Martin Hammer,et al.  Fluorescence Lifetime Imaging Ophthalmoscopy: A Novel Way to Assess Macular Telangiectasia Type 2. , 2017, Ophthalmology. Retina.

[17]  E. Chew,et al.  ABNORMAL RETINAL REFLECTIVITY TO SHORT-WAVELENGTH LIGHT IN TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA , 2017, Retina.

[18]  E. Chew,et al.  CHARACTERISTICS OF PIGMENTED LESIONS IN TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA , 2014, Retina.

[19]  U. Grünert,et al.  Disruption of De Novo Serine Synthesis in Müller Cells Induced Mitochondrial Dysfunction and Aggravated Oxidative Damage , 2018, Molecular Neurobiology.

[20]  Sebastian Wolf,et al.  FUNDUS AUTOFLUORESCENCE LIFETIMES AND CENTRAL SEROUS CHORIORETINOPATHY , 2017, Retina.

[21]  H. Arai,et al.  An atypical case of SPG56/CYP2U1-related spastic paraplegia presenting with delayed myelination , 2017, Journal of Human Genetics.

[22]  M. Hammer,et al.  Fluorescence lifetime imaging ophthalmoscopy , 2017, Progress in Retinal and Eye Research.

[23]  Melanie Bahlo,et al.  Genome-wide analyses identify common variants associated with macular telangiectasia type 2 , 2017, Nature Genetics.

[24]  B. Garavaglia,et al.  Long-term follow-up in spastic paraplegia due to SPG56/CYP2U1: age-dependency rather than genetic variability? , 2017, Journal of Neurology.

[25]  T. Hornemann,et al.  Localization of 1-deoxysphingolipids to mitochondria induces mitochondrial dysfunction[S] , 2016, Journal of Lipid Research.

[26]  M. Cowley,et al.  Defining the genetic basis of early onset hereditary spastic paraplegia using whole genome sequencing , 2016, neurogenetics.

[27]  R. Schüle,et al.  CYP2U1 mutations in two Iranian patients with activity induced dystonia, motor regression and spastic paraplegia. , 2016, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[28]  F. Pierelli,et al.  Pigmentary degenerative maculopathy as prominent phenotype in an Italian SPG56/CYP2U1 family , 2016, Journal of Neurology.

[29]  A. Tessa,et al.  Hereditary spastic paraplegia: Novel mutations and expansion of the phenotype variability in SPG56. , 2015, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[30]  A. Bird,et al.  Macular Telangiectasia Type 2 Without Clinically Detectable Vasculopathy. , 2015, JAMA ophthalmology.

[31]  A. Merrill,et al.  1-Deoxysphingolipids Encountered Exogenously and Made de Novo: Dangerous Mysteries inside an Enigma* , 2015, The Journal of Biological Chemistry.

[32]  G. Stevanin,et al.  Delving into the complexity of hereditary spastic paraplegias: how unexpected phenotypes and inheritance modes are revolutionizing their nosology , 2015, Human Genetics.

[33]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[34]  F. Santorelli,et al.  Hereditary spastic paraplegia: Clinical-genetic characteristics and evolving molecular mechanisms , 2014, Experimental Neurology.

[35]  Gwénolé Quellec,et al.  Quantitative analysis of fluorescence lifetime measurements of the macula using the fluorescence lifetime imaging ophthalmoscope in healthy subjects. , 2014, Investigative ophthalmology & visual science.

[36]  N. Bresolin,et al.  Mutations in CYP2U1, DDHD2 and GBA2 genes are rare causes of complicated forms of hereditary spastic paraparesis , 2014, Journal of Neurology.

[37]  J. Fink,et al.  Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms , 2013, Acta Neuropathologica.

[38]  Emily Y. Chew,et al.  Macular telangiectasia type 2 , 2013, Progress in Retinal and Eye Research.

[39]  G. Gyapay,et al.  Alteration of fatty-acid-metabolizing enzymes affects mitochondrial form and function in hereditary spastic paraplegia. , 2012, American journal of human genetics.

[40]  Catherine Egan,et al.  The IS/OS junction layer in the natural history of type 2 idiopathic macular telangiectasia. , 2012, Investigative ophthalmology & visual science.

[41]  A. Destée,et al.  Spastic paraplegia gene 7 in patients with spasticity and/or optic neuropathy. , 2012, Brain : a journal of neurology.

[42]  Catherine Egan,et al.  "En face" OCT imaging of the IS/OS junction line in type 2 idiopathic macular telangiectasia. , 2012, Investigative ophthalmology & visual science.

[43]  Krzysztof Kiryluk,et al.  Identification of a Potential Susceptibility Locus for Macular Telangiectasia Type 2 , 2012, PloS one.

[44]  Irene Leung,et al.  The Prevalence of Type 2 Idiopathic Macular Telangiectasia in Two African Populations , 2012, Ophthalmic epidemiology.

[45]  Tunde Peto,et al.  Analysis of candidate genes for macular telangiectasia type 2 , 2010, Molecular vision.

[46]  T. Hornemann,et al.  Mutations in the SPTLC2 subunit of serine palmitoyltransferase cause hereditary sensory and autonomic neuropathy type I. , 2010, American journal of human genetics.

[47]  Ronald Klein,et al.  The prevalence of macular telangiectasia type 2 in the Beaver Dam eye study. , 2010, American journal of ophthalmology.

[48]  J. Cruysberg,et al.  Patients with Sjögren-Larsson syndrome lack macular pigment. , 2010, Ophthalmology.

[49]  R. Guymer,et al.  THE PREVALENCE ESTIMATES OF MACULAR TELANGIECTASIA TYPE 2: The Melbourne Collaborative Cohort Study , 2010, Retina.

[50]  T. Hornemann,et al.  Hereditary Sensory Neuropathy Type 1 Is Caused by the Accumulation of Two Neurotoxic Sphingolipids*♦ , 2010, The Journal of Biological Chemistry.

[51]  M. Crossland,et al.  FIXATION STABILITY MEASUREMENT USING THE MP1 MICROPERIMETER , 2009, Retina.

[52]  M. Taimi,et al.  CYP2U1, a novel human thymus- and brain-specific cytochrome P450, catalyzes omega- and (omega-1)-hydroxylation of fatty acids. , 2004, The Journal of biological chemistry.

[53]  B. Blodi,et al.  Idiopathic juxtafoveolar retinal telangiectasis , 1993 .